The standard 0.5 mg starting protocol A 0.5 mg weekly starting dose has become increasingly popular outside of formal clinical trials
Finally, a four-year, multicenter, clinical trial in 421 diabetic patients with distal symmetric sensorimotor polyneuropathy found no difference between oral administration of 600 mg/day of lipoic and placebo on the primary endpoint, a composite score that assessed neuropathic impairment of the lower limbs and nerve conduction (78)
Starting with smaller amounts allows the human body to adjust gradually
This compound is known for its multifaceted benefits, ranging from cognitive enhancement and neuroprotection to supporting energy levels and mood regulation
Additionally, both agents influence lipid metabolism, albeit differently
It has been FDA-approved since 2014 and produced average weight loss of 5-8% of body weight in clinical trials